Skip to main content
SCM Lifescience Co., Ltd. logo

SCM Lifescience Co., Ltd. — Investor Relations & Filings

Ticker · 298060 ISIN · KR7298060005 KO Manufacturing
Open in API
Filings indexed 418 across all filing types
Latest filing 2023-09-22 Director's Dealing
Country KR South Korea
Listing KO 298060

About SCM Lifescience Co., Ltd.

http://www.scmlifescience.com/en/

SCM Lifescience Co., Ltd. is a biotechnology company focused on developing high-purity, high-efficacy stem cell therapeutics for difficult-to-treat and incurable diseases. The company utilizes its proprietary source technology, the Subfractionation Culturing Method, to isolate and culture potent stem cells. Its pipeline consists of allogeneic stem cell therapies targeting immunological conditions, which are undergoing clinical trials. SCM Lifescience is also establishing mass production manufacturing processes using 3D bioreactor technology and expanding its research into induced pluripotent stem cells (iPSC) and tissue engineering. The company's business areas also include contract manufacturing (CMO), contract research, consulting, and cosmetics.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by corporate insiders to report changes in their shareholdings. This corresponds to the 'Director's Dealing' category, which covers insider trades and changes in ownership by company directors and executives.
2023-09-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. This is a standard regulatory filing in South Korea used to disclose changes in shareholdings by company insiders (directors/executives). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2023-09-22 Korean
증권발행결과(자율공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a securities issuance (capital increase via rights offering) by SCM Lifescience. It details the number of shares issued, the amount raised, and the payment completion date. This falls under the category of capital changes and share issuance announcements.
2023-09-14 Korean
증권발행실적보고서
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed with the Financial Supervisory Service (FSS) in South Korea. It details the final results of a capital increase (rights offering), including subscription status, allocation, use of proceeds, and shareholding changes. This document is a standard regulatory filing required after the completion of a capital raising event. Among the provided categories, 'SHA' (Share Issue/Capital Change) is the most accurate fit as it specifically covers announcements regarding new share issues and capital changes.
2023-09-14 Korean
권리락(무상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a short announcement regarding a 'rights off' (권리락) event due to a bonus issue (무상증자) for SCM Lifescience. It provides specific details such as the reference price and the effective date. This falls under the category of capital changes or share issues, specifically fitting the 'Share Issue/Capital Change' category.
2023-09-14 Korean
유상증자또는주식관련사채등의청약결과(자율공시)
Capital/Financing Update Classification · 100% confidence The document is an official regulatory filing from the Korea Exchange (KRX) regarding the results of a capital increase (rights offering and public offering). It details the subscription results, including the number of shares subscribed, subscription rates, and the allocation process for the capital raise. This falls under the category of capital and financing updates as it relates to the company's capital structure changes.
2023-09-13 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.